An observational study in External Causes of Morbidity and Mortality, sponsored by Ruhr University of Bochum. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2018-10-19.
Sponsored by Ruhr University of Bochum · Observational
Longterm followup of patients with rheumatoid arthritis 30 years after starting a baseline treatment with Methotrexate.
Objective. 30-year follow-up of rheumatoid arthritis (RA) patients treated with methotrexate (MTX) in the 1980s to analyze the association of the degree of response to MTX with long-term mortality.
Methods. In this observational cohort study, 271 RA patients who had started treatment with MTX between 1980 and 1987 were included (mean age 58 years, mean disease duration 8.5 years). One year after baseline, the treatment response to MTX was evaluated. Responders were defined as patients with at least 20% improvement. Thereafter, assessments were performed at 10 and 18 years after baseline. This re-evaluation was done to provide the data after 30 years of follow-up. Standardized mortality ratios (SMR) are calculated, Cox regression and logistic regression are performed.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 271 is above the median of 155 across 1,057 observational studies indexed under Arthritis.
Browse Arthritis studies →Ruhr University of Bochum is the lead sponsor of 124 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with rheumatoid arthritis
Exclusion Criteria:
mortality
Time frame: 30 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ruhr University of Bochum